Our latest news on Magmaris RMS

17
May
2022
| 09:32 Europe/Amsterdam

EuroPCR: Magmaris Resorbable Magnesium Scaffold Confirms High Safety Profile at 3 Years With BIOSOLVE-IV Data

Two poster sessions at EuroPCR focus on Magmaris’ safety profile for the first cohort after three years and the full cohort subgroup analysis at one-year follow-up

Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski,
08
November
2021
| 09:09 Europe/Amsterdam

Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) in Scaffold Thrombosis shown versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Largest Patient Cohort to Date

BIOSOLVE-IV Registry one-year follow up data, analyzing 2,066 patients showed Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Scaffold Thrombosis*

Superiority of the Magmaris sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data
18
May
2021
| 09:00 Europe/Amsterdam

Real-World Data Confirms Long-Term Safety and Efficacy of BIOTRONIK’s Bioresorbable Scaffold

BIOSOLVE-IV registry two-year data show low event rates for the Magmaris RMS, comparable to second generation drug-eluting stents

New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients
15
November
2020
| 17:56 Europe/Amsterdam

Future of Resorbable Scaffolds Looks Rosier

As more data comes in, there’s plenty of reasons to be optimistic about scaffolds

In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the
30
September
2019
| 00:00 Europe/Amsterdam

TCT 2019: Real-World Registry Data Confirm Safety of Resorbable Scaffold Technology

Magmaris Scaffold Shows Low Complication Rates, Benefiting Patients with Both Stable and Unstable Coronary Artery Disease

Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery
07
June
2019
| 00:00 Europe/Amsterdam

EuroPCR 2019: New Data Confirms Future of Resorbable Magnesium Scaffolds

Registries Show Magmaris’ Safety While Development Insights Offer Promising Prospects for Magnesium-Based Scaffolds

New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior